Navigation Links
Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
Date:9/3/2009

SAN DIEGO, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the following investor conferences:

  • Robert W. Baird 2009 Health Care Conference on Wednesday, September 9, 2009 at 10:30 a.m. Eastern Time at the Four Seasons Hotel in New York City.
  • Thomas Weisel Partners 2009 Healthcare Conference on Thursday, September 10, 2009 at 3:50 p.m. Eastern Time at the Four Seasons Hotel in Boston.
  • ThinkEquity's 6th Annual Growth Conference on Tuesday, September 15, 2009 at 10:30 a.m. Pacific Time at the St. Regis Hotel in San Francisco.
  • UBS Global Life Sciences Conference 2009 on Tuesday, September 22, 2009 at 1:00 p.m. Eastern Time at the Grand Hyatt New York in New York City.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

Live audio webcasts of these presentations will be accessible on the Investors page of the Company's website at www.optimerpharma.com, under the investors section. Replays of these presentations will be available at the same location for 30 days following the meeting.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, forme
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
2. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
3. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
4. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
5. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
6. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
7. Arena Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
8. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
9. Onyx Pharmaceuticals to Present at Two Upcoming Healthcare Conferences
10. Transcept Pharmaceuticals to Present at the BioCentury Thomson Reuters Newsmakers in the Biotech Industry Conference on September 16, 2009
11. Poniard Pharmaceuticals To Present at Three Upcoming Investor Conferences in September
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Based on the revenues gained from ... is dominated by four major players contributing to ... players include GE Healthcare (U.K.), Siemens AG (Germany), ... Full Report Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html , ... attributed to its strong product portfolio, which includes ...
(Date:12/17/2014)... December 17, 2014 Once more, EMAAR ... a larger packaged waste water treatment plant to phase ... Economic City (KAEC). Two years ago Bioshaft successfully supplied ... Development, serving two residential towers with an occupancy of ... a quarter million gallons per day and was signed ...
(Date:12/17/2014)... 17, 2014 Audacity, a leading California-based ... member of the Huntsworth Health Group, is proud to ... team. In her role, Gonzales will serve as Senior ... incredibly honored to welcome a talent of Jamie’s caliber ... Gaëtan Fraikin. “She is a proven healthcare innovation leader ...
(Date:12/17/2014)... 17, 2014 Tigercat Pharma, Inc. today ... evaluating the investigational oral NK-1 receptor antagonist VPD-737 ... chronic itch who are unresponsive or inadequately responsive ... steroids and antihistamines. The primary ... Scale (VAS) itch score from baseline, comparing drug ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... Chest Physicians (ACCP) Guidelines Will Increase ... Use of Trellis(R) Peripheral Infusion System, NORTHBROOK, ... (ACCP) has published new evidence-based clinical guidelines for,physicians that ... for acute iliofemoral deep vein thrombosis (DVT) in,conjunction with ...
... are everywhere from the air we breathe and the food ... are innocuous or even beneficial, and only a handful pose any ... unwanted intruder? , Research from the University of Wisconsin-Madison suggests ... , A study appearing online this week in the Proceedings ...
... Ardea Biosciences, Inc.,(Nasdaq: RDEA ) today ... the,Company,s novel investigational non-nucleoside reverse transcriptase,inhibitor (NNRTI) for ... Annual ICAAC/IDSA 46th Annual Meeting in Washington, DC ... of HIV Research, Chelsea and Westminster,Hospital, will present ...
Cached Biology Technology:Chest Physicians Now Suggest Early Intervention for Certain Blood Clots in DVT 2Symbiotic microbes induce profound genetic changes in their hosts 2Ardea to Present Data on Lead HIV Candidate, RDEA806, at ICAAC/IDSA Joint Meeting 2Ardea to Present Data on Lead HIV Candidate, RDEA806, at ICAAC/IDSA Joint Meeting 3
(Date:12/10/2014)... -- Valencell, a leader in performance biometric data sensor technology, ... its licensees for highly accurate, clinically validated biometric technology. ... from fitness and health sectors, but first responders/military and ... only as useful as the biometric data it delivers. ... long-term mass consumer adoption of wearable products," said Dr. ...
(Date:12/10/2014)... California , December 9, 2014 ... with ITN,s BCARD Platform   ... cloud-based enterprise meeting scheduling solutions for business-to-business (B2B) ... the world leader in mobile near-field communication (NFC), ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , ...
(Date:12/3/2014)... 2014   Marvin Test Solutions , a ... for military, aerospace, and manufacturing organizations, today announced ... TS-900 PXI semiconductor test platform . The ... systems to customers at a fraction of the ... ATE. "Our semiconductor customers asked ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... atomic bomb, Niels Bohr* worked tirelessly to promote a ... highly relevant in a world where internet surveillance and ... warfare raise questions about not just openness but also ... of the celebrations of the 100th anniversary of Bohr,s ...
... comprehensive, quality-controlled dataset that gives ready access to millions ... Horizon Oil Spill. The dataset, collected to support oil removal ... three year process that began with the gathering of water ... during and after the oil release in 2010. ...
... A technology-driven concept, a safe city is ... better use of intelligence. The four pillars of ... multi-agency collaboration, shared command & control, and intelligence ... a developed environment, assurance of safety for citizens ...
Cached Biology News:International Niels Bohr Conference: An open world 2NOAA launches website holding millions of chemical analyses from Deepwater Horizon oil spill 2Frost & Sullivan: Safe Cities to directly impact First Responder and Biometric markets positively 2Frost & Sullivan: Safe Cities to directly impact First Responder and Biometric markets positively 3Frost & Sullivan: Safe Cities to directly impact First Responder and Biometric markets positively 4Frost & Sullivan: Safe Cities to directly impact First Responder and Biometric markets positively 5
... Software reads and processes raw ... microarray data for analysis. ... one 1-year license for Feature ... ,one CD-ROM containing Feature Extraction ...
... CHEMICONs ELF 97 Cytological Labeling Kit provides ... the detection of cellular targets, including cell-surface ... Cytological Labeling Kit contains the patented ELF ... fluorescent yellow-green precipitate at the site of ...
... Many differences exist between the various commercial ... glass slide used, the length and GC ... and the manufacturing protocol employed all influence ... analysis. With all the different variables ...
... SYBR Safe DNA Gel Stain combo offers these benefits: ... these same products separately ... Eliminates risks to yourself, ... RNA fragments from 100 bp to >30 kb. UltraPure ...
Biology Products: